Constructive Bio

Constructive Bio is pioneering a dual-technology platform combining whole-genome synthesis and engineered translation to reprogram the genetic code of microorganisms. This enables the scalable, fermentation-based production of peptide and protein therapeutics containing precisely placed non-canonical amino acids, unlocking new chemistries and functions. The company is positioned to create next-generation drug candidates, such as stabilized GLP-1 analogs and site-specific antibody-drug conjugates, with potential advantages in stability, efficacy, and target engagement. Its foundational science is based on peer-reviewed research from Professor Jason Chin's lab.

Dual-technology platform combining whole-genome synthesis (Syn61/Syn57 recoded E. coli) and engineered translation systems to incorporate over 300 non-canonical amino acids (ncAAs) into peptides and proteins via fermentation.

Competitors include other synthetic biology companies engineering the genetic code (e.g., GRO Biosciences, Pearl Bio) and protein engineering firms using alternative conjugation or synthesis techniques. Constructive Bio differentiates through its complete genome recoding, vast ncAA library, and aim for multi-ncAA incorporation via scalable fermentation.